biotech firms expanding glp-1 use beyond diabetes and obesity 2025 How a Pre-Revenue Anti-Obesity Became Pharma's Most Coveted Target: Inside the $10bn Bidding War for Metsera – Bocconi Students M&A Circle GLP-1 Market Size to Hit

Eli Lilly is expecting results from several more phase 3 trials of retatrutide for obesity and type 2 diabetes this year, a spokesperson told Scientific American

Moreover, it is unclear whether people taking GLP-1s who also have opioid use disorder are those who are using the riskiest drugs

Act 3: The Stacking Question What Longevity Experts Say About Combining Both The most sophisticated practitioners in the longevity space don't typically ask, "Should I use GLP-1 or BPC-157?" Instead, they ask, "When does each one belong in a protocol, and can they safely coexist?" The Complementary Logic Longevity-focused physicians and sports medicine practitioners have begun articulating a clear rationale for combining these compounds in specific patient profiles: The GLP-1 Layer: Addresses the metabolic side (reducing fat, improving insulin, lowering cardiovascular risk)

How Diet and Exercise Impact GLP-1 Levels Naturally Lifestyle behaviors influence GLP-1 production

But alternatives exist: Lower doses Different drugs (some report fewer side effects with Mounjaro vs

If your primary concern is being able to actually keep the electrolytes down, citrate formulations are worth prioritizing